| Cat.No. | Name | Information |
|---|---|---|
| M2353 | 10074-G5 | 10074-G5 is a c-Myc/Max interaction inhibitor, which binds to a different specific binding site (region) of C-Myc than 10054-F4. |
| M2352 | 10058-F4 | 10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. |
| M59313 | MYC-IN-3 | MYC-IN-3 is a potent MYC inhibitor. MYC-IN-3 shows antiproliferative and anticancer activity. MYC-IN-3 inhibits the binding of MYC/MYC-associated protein X (MAX) heterodimer to DNA consensus sequence, induce MYC thermal instability, and disturb MYC/MAX interaction. |
| M30320 | KJ Pyr 9 | KJ Pyr 9 is an inhibitor of MYC with a Kd of 6.5 nM in in vitro assay. |
| M29215 | WBC100 | WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c‐Myc molecule glue degrader. WBC100 is a c‐Myc degrader and targets ubiquitin E3 ligase CHIP mediated 26S proteasome pathway. WBC100 is used for c‐Myc overexpressing tumors research. |
| M20729 | MYCi361 | MYCi361 is a MYC inhibitor that engages MYC inside cells, disrupts MYC/MAX dimers, and impairs MYC-driven gene expression. MYCi361 binds to MYC with Kd of 3.2 μM. MYCi361 suppresses in vivo tumor growth, increases tumor immune cell infiltration, upregulates PD-L1 on tumors, and sensitizes tumors to anti-PD1 immunotherapy. |
| M13541 | Mycro 3 | Mycro 3 is a potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3 could be used for the research of pancreatic cancer. |
| M13540 | IZCZ-3 | IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity. |
| M13539 | APTO-253 | APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. |
| M11420 | MYCi975 | MYCi975 (Nuc-0200975) is an orally active MYC inhibitor that disrupts MYC/MAX interactions, promotes MYC T58 phosphorylation and MYC degradation, and impairs myC-driven gene expression. MYCi975 (NUC-0200975) has strong anti-tumor effect and good tolerance, increasing tumor immune cell infiltration and enhancing tumor sensitivity against PD1 immune studies. |
| M9309 | ML327 | ML327 is a blocker of MYC, which mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. |
| M41339 | MDEG-541 | MDEG-541 is a potent MYC-MAX degrader. |
| M41338 | c-Myc inhibitor 11 | c-Myc inhibitor 11 is a c-MYC inhibitor (pEC50: 6.4). |
| M41337 | c-Myc inhibitor 12 | c-Myc inhibitor 12 is an inhibitor of c-Myc with a pEC50 of 6.4. |
| M41336 | m-Se3 | m-Se3 is a potent and selective c-MYC transcription inhibitor that can inhibit tumor growth and has anti-cancer activity. |
| M41335 | c-Myc inhibitor 10 | c-Myc inhibitor 10, a c-Myc inhibitor, exhibits increased cellular potency, consistent with an increase in permeability with methylation of the morpholine nitrogen. |
| M41334 | MYC-RIBOTAC | MYC-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) to MYC internal ribosome entry site (IRES). |
| M30814 | NY2267 | NY2267 is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM. NY2267 inhibits Myc- and Jun-induced transcriptional activation. |
| M30474 | MYCMI-6 | MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5 μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis. |
| M29830 | c-Myc inhibitor 9 | c-Myc inhibitor 9 (compound 332) is a c-Myc inhibitor with an logEC50 of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
